Two new vaccine advisers tapped by Health and Human Services Secretary Robert F. Kennedy Jr. have served as paid expert ...

Merck & Co. Inc. closed 39.23% short of its 52-week high of $134.63, which the company reached on June 25th.

Martin Kulldorff, appointed by RFK Jr. to a federal vaccine panel, previously earned $33K as an expert witness in lawsuits ...

Health and Human Services Secretary Robert F. Kennedy, Jr., has announced new members of the Centers for Disease Control and Prevention’s vaccine advisory panel. At such a critical moment in US ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an ...

One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an ...

In Merck’s case, worries over rising competition from so-called ‘biosimilar’ generic products, which approximate the biological chemical structure of branded medicines, is behind much of the ...

THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial ...

Merck KGaA has shed more light on the failure of its lupus drug in one cohort of patients, while pointing to secondary ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.